Alnylam Pharmaceuticals
MA · 24 filings, 2025
What the money shows
Alnylam Pharmaceuticals reported $1.6M in federal lobbying for 2025 across 24 filings. The filings name 6 lobbying firms, led by Capitol Counsel and LMH Strategic Solutions. The matched PAC file shows $20,000 to 0 lawmakers. The filing text lists 5 issue areas.
Sources: Senate LDA · FEC
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. via Wikipedia ↗
1Lobbies on
Its filings list: Medicare/Medicaid · Medical/Disease Research/Clinical Labs · Trade (domestic/foreign) · Pharmacy · Veterans
2Through these firms · 6
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5242A bill to provide for digital communication of prescribing information for drugs (including biological prod…
- HR 10033Rules for self-driving cars and emergency crews
4And its PAC funds these lawmakers · 2
No democrats on file.